Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

REC 0/0559 Colírio para Tratamento de Ceratite Neurotrófica Moderada e Grave em Pacientes Adultos

14 de setembro de 2026 atualizado por: RECORDATI GROUP

Eficácia, Segurança e Farmacocinética de 3 Doses de Colírio REC 0/0559 para Tratamento de Ceratite Neurotrófica Estágio 2 (Moderada) e 3 (Grave) em Pacientes Adultos

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

This was a Phase 2, international, multicentre, dose-ranging, double-masked, randomised, parallel-group, vehicle-controlled study designed to evaluate 3 different doses of REC 0/0559 vs vehicle in patients with Stage 2 and Stage 3 neurotrophic keratitis (NK).

Tipo de estudo

Intervencional

Inscrição (Real)

108

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Cologne, Alemanha, 50924
        • Uniklinik Koeln
      • Düsseldorf, Alemanha, 40225
        • Hospital Eye University of Duesseldorf
      • Frankfurt, Alemanha, 60590
        • Universitaetsklinikum Frankfurt
      • Homburg, Alemanha
        • Saarland University Medical Center
      • Mainz, Alemanha, 55131
        • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
    • Bavaria
      • Munich, Bavaria, Alemanha, 80336
        • Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik
      • Barakaldo, Espanha, 48903
        • Hospital de Cruces
      • Barcelona, Espanha
        • Centro de Oftalmologia Barraquer
      • Barcelona, Espanha, 08035
        • Instituto Microcirugia Ocular IMO
      • Madrid, Espanha, 28040
        • Hospital Clinico San Carlos
      • Seville, Espanha
        • Cartuja Vision - Centro de Servicios Oftlamologicos
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Espanha, 33012
        • Instituto Oftalmologico Fernandez-Vega
    • Florida
      • Crystal River, Florida, Estados Unidos, 34429-8722
        • Nature Coast Clinical Research
      • Gainesville, Florida, Estados Unidos, 32605
        • University of Florida
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland School of Medicine UMSOM
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48105
        • University of Michigan - Kellogg Eye Center
    • New York
      • New York, New York, Estados Unidos, 10003
        • Mt. Sinai New York Eye and Ear Infirmary
    • North Carolina
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Wake Forest Baptist Medical Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37215
        • Toyos Clinic
    • Texas
      • Houston, Texas, Estados Unidos, 77025
        • Houston Eye Associates HEA - Gramercy Location
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53705
        • University of Wisconsin-Madison
      • Dijon, França, 21000
        • Dijon University Hospital CHU Dijon
      • Paris, França
        • Hôpital Fondation Adolphe de Rothschild
      • Paris, França, 75014
        • CHU Paris Centre - Hôpital Cochin
      • Paris, França
        • Hôpital Universitaire Necker
      • Budapest, Hungria
        • Semmelweis University, Dept. of Ophthalmology
      • Pécs, Hungria
        • University of Pecs - Dpt of Ophthalmology
    • Vas County
      • Szombathely, Vas County, Hungria, 9700
        • Markusovszky University Teaching Hospital
      • Bari, Itália, 70124
        • Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica
      • Bologna, Itália, 40138
        • DIMES Universit di Bologna
      • Florence, Itália, 50134
        • Azienda Ospedaliero-Universitaria Careggi
      • Forlì, Itália
        • Ospedali Privato
      • Genova, Itália, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Messina, Itália
        • Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
      • Milan, Itália, 20157
        • Ospedale Luigi Sacco
      • Roma, Itália, 00133
        • Fondazione PTV - Policlinico Tor Vergata
    • Calabria
      • Germaneto, Calabria, Itália, 88100
        • Università Magna Grecia di Catanzaro
      • Glasgow, Reino Unido, G75 8RG
        • University Hospital Hairmyres
      • London, Reino Unido
        • Moorfields Eye Hospital NHS Foundation Trust
      • Southampton, Reino Unido, SO16 6YD
        • Southampton General Hospital
    • Mersey
      • Liverpool, Mersey, Reino Unido, L7 8XP
        • Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Have read, understood, and signed the informed consent form (ICF).

  2. Be a male or female aged ≥18 years at the time of ICF signature.

  3. Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.

    for the study eye

  4. Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.

  5. Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.

  6. Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.

Exclusion Criteria:

  1. Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.

  2. Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8

  3. Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.

  4. Have a significant history of alcohol abuse or drug/solvent abuse

  5. Be unwilling to comply with any study assessments or procedures.

  6. Be a woman who is pregnant, nursing or planning a pregnancy.

  7. Be a woman of childbearing potential not using a highly effective method of birth control.

  8. Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.

    For the study eye:

  9. Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.

  10. Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),

  11. Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).

  12. Have severe blepharitis and/or severe meibomian gland disease in the study eye.

  13. Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.

  14. Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.

  15. Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.

  16. Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.

  17. Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.

  18. Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.

  19. Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.

  20. Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.

    For the fellow eye

  21. Have Stage 2 or 3 NK or perforation.

    For any eye:

  22. Have a history of ocular cancer.

  23. Have had prior treatment with Oxervate™

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose 1 - 0.5 µg/day

Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Outros nomes:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Experimental: Dose 2 - 2.5 µg/day

Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Outros nomes:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Experimental: Dose 3 - 5 µg/day

Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Outros nomes:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Comparador de Placebo: Vehicle

Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID

Eye drop solution with no active substance in single dose unit.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Corneal Healing
Prazo: At week 8

The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre.

At week 8

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Visual Acuity
Prazo: At week 8

Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively).

At week 8

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

13 de outubro de 2020

Conclusão Primária (Real)

29 de abril de 2024

Conclusão do estudo (Real)

29 de abril de 2024

Datas de inscrição no estudo

Enviado pela primeira vez

17 de fevereiro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de fevereiro de 2020

Primeira postagem (Real)

19 de fevereiro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • REC0559-B-001

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .